Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Net Cash Flow (2024 - 2025)

Xilio Therapeutics' Net Cash Flow history spans 2 years, with the latest figure at -$17.8 million for Q3 2025.

  • For Q3 2025, Net Cash Flow fell 29.93% year-over-year to -$17.8 million; the TTM value through Sep 2025 reached $42.5 million, changed N/A, while the annual FY2024 figure was $10.8 million, 114.25% up from the prior year.
  • Net Cash Flow for Q3 2025 was -$17.8 million at Xilio Therapeutics, down from $32.5 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $40.0 million in Q2 2024 and bottomed at -$17.8 million in Q3 2025.